hCAIX-IN-12 

hCAIX-IN-12 is a potent hCAIX inhibitor with IC₅₀ values of 0.74, 10.78 µM for CAIX and CAII, respectively. hCAIX-IN-12 shows antiproliferative effect and induces apoptosis. hCAIX-IN-12 increases ROS production. hCAIX-IN-12 has the potential for the research of colorectal cancer (CRC) ^[1].

IC₅₀: 0.74 µM (CAIX); 10.78 µM (CAII)^[1].

hCAIX-IN-12 (compound OX27) shows antiproliferative effect with IC₅₀s of 6.0 µM for HCT-116 cells^[1].
hCAIX-IN-12 decreases the expression of CAIX in HCT-116 cells and inhibits the expression of CAIX more pronouncedly in hypoxic conditions^[1].
hCAIX-IN-12 (0-50 µM; 0-48 h) inhibits the colony formation in a dose-dependent manner and 7 inhibits the migration of HCT-116 cells^[1].
hCAIX-IN-12 (6.0 µM; 48 h) induces apoptosis in HCT-116 cells^[1].
hCAIX-IN-12 (6.0 µM; 24,48 h) increases in the levels of ROS in HCT-116 cells^[1].
hCAIX-IN-12 causes depletion of HCT-116 cells in the G0/G1 (P2 65.21%) phase with an increase in the accumulation of cells in G2/M (P4 18.95%) phase^[1].
hCAIX-IN-12 has high binding affinity for CAIX and substantial affinity for HSA^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

398.46

C₁₈H₁₄N₄O₃S₂

2414598-85-7

O=S(C1=CC=C(N)C=C1)(NC2=C(C3=NC(C4=CC=CC=C4)=NO3)SC=C2)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Shamsi F, et al. Synthesis and SAR studies of novel 1,2,4-oxadiazole-sulfonamide based compounds as potential anticancer agents for colorectal cancer therapy. Bioorg Chem. 2020 May;98:103754.  [Content Brief]